Vidaza is said to significantly extend the life of patients with myelodysplastic syndrome. In a late-stage study, results showed that taking Vidaza extends the median survival of 15 months for those on conventional treatments to 24.4 months. Shortly before 1:30 p.m., Pharmion shares were trading at $37.60, up 52% from Wednesday's $24.64 close.
Major mover: Pharmion (PHRM) jumps by half
Posted Aug 2nd 2007 1:27PM by Kelly Wu
Filed under: Major movement
Vidaza is said to significantly extend the life of patients with myelodysplastic syndrome. In a late-stage study, results showed that taking Vidaza extends the median survival of 15 months for those on conventional treatments to 24.4 months. Shortly before 1:30 p.m., Pharmion shares were trading at $37.60, up 52% from Wednesday's $24.64 close.
Before the bell: Futures higher ahead of housing, jobless data
Nuclear power is on the comeback trail
Apple backs AT&T in continuing spat with Verizon
